Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer



Status:Recruiting
Conditions:Prostate Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:11/8/2014
Start Date:December 2013
End Date:December 2016
Contact:Exelixis Clinical Trials
Phone:1-888-393-5494

Use our guide to learn which trials are right for you!

A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination With Abiraterone in Chemotherapy Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer

This study is designed to evaluate the safety and efficacy of combining abiraterone (with
prednisone) with cabozantinib in chemotherapy-naïve subjects with bone-metastatic
castration-resistant prostate cancer (CRPC).


Inclusion Criteria:

- Histologically or cytologically confirmed adenocarcinoma of the prostate.

- Must be surgically or medically castrated (serum testosterone levels less than or
equal to 50 ng/dL)

- Must have castration-resistant prostate cancer (CRPC) with disease progression during
LHRH therapy or after a surgical bilateral orchiectomy.

- Bone metastasis related to prostate cancer

- Adequate organ and marrow function

- Capable of understanding and complying with the protocol requirements and signed the
informed consent document

- Sexually active subjects and their partners must agree to use medically accepted
methods of barrier contraception (eg, male condom or female condom) as well as one
other medically accepted method of contraception during the course of the study
treatment and for 4 months after the last dose of study treatment.

Exclusion Criteria:

- Any prior treatment with abiraterone, enzalutamide, or any investigational agents
blocking androgen receptor (AR) or androgen synthesis.

- Any prior treatment with cabozantinib or participation in a prior clinical trial of
cabozantinib.

- Any prior cytotoxic therapy (including estramustine) or biologic therapy for the
treatment of prostate cancer (a few exceptions will be allowed)

- Any prior radionuclide therapy (eg, samarium 153, strontium 89, alpharadin)

- Use of investigational agent within 28 days

- Any pathological finding consistent with small cell carcinoma of the prostate

- Known brain metastases or cranial epidural disease

- Diagnosis of another malignancy within 2 years, except for superficial non-melanoma
skin cancers, or localized, low grade tumors deemed cured and not treated with
systemic therapy
We found this trial at
20
sites
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Athens, GA
Click here to add this to my saved trials
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Charleston, South Carolina 29412
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Greenville, South Carolina 29605
?
mi
from
Greenville, SC
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Myrtle Beach, South Carolina 29572
?
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
?
mi
from
Oxnard, CA
Click here to add this to my saved trials
?
mi
from
Peoria, IL
Click here to add this to my saved trials
?
mi
from
Raleigh, NC
Click here to add this to my saved trials
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
?
mi
from
San Diego, CA
Click here to add this to my saved trials
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
?
mi
from
Sedona, AZ
Click here to add this to my saved trials
?
mi
from
Tualatin, OR
Click here to add this to my saved trials
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
?
mi
from
Wichita, KS
Click here to add this to my saved trials